At a glance
| Ingredient context | Original Eyeseryl |
|---|---|
| Chemical class | Acetylated tetrapeptide |
| Main marketing area | Eye-contour appearance |
| Evidence issue | Few isolated-ingredient controlled data |
| Route boundary | Topical cosmetics and injections are separate |
Overview
The ingredient’s identity is more specific than the general category eye peptide: acetyl tetrapeptide-5 has a defined four-residue structure and is associated with the Eyeseryl name. Eye-contour appearance can reflect pigment, fluid, skin texture, and underlying anatomy, so a single cosmetic claim can hide several different endpoints. Supplier descriptions and product availability establish commercial use, not a clinically proven treatment for eyelid swelling. Newer products carrying expanded versions of a trade name may also contain different peptides. The actual ingredient list matters more than assuming every similarly named eye-care product is chemically identical.
How it works
The cosmetic concept concerns the appearance of puffiness and the surrounding skin, but an independently established clinical mechanism for the isolated ingredient was not demonstrated in the sources checked. Claims about fluid movement, vascular permeability, or collagen protection need direct testing. Changes after a formulation containing hyaluronic acid, amino acids, and this peptide cannot identify which pathway, if any, was specifically influenced by acetyl tetrapeptide-5.
A recent combination study does not isolate the peptide
A 2026 single-arm study of forty women assessed an injected hyaluronic-acid and amino-acid product that also contained an Eyeseryl complex. Ultrasound and elasticity measurements changed after treatment. There was no untreated or placebo comparison, and the authors acknowledged confounding. The study cannot establish that acetyl tetrapeptide-5 caused the changes or that a topical product would reproduce them.
Supporting sources [1]
What supplier records establish
Lubrizol identifies an Eyeseryl peptide solution product, while a research-material safety sheet specifies acetyl tetrapeptide-5’s chemical identity. Those records support naming and material characterization. They are not controlled evidence that a consumer cream reduces all causes of under-eye swelling or that research powder is suitable for human treatment.
Limits of the cosmetic category
Cosmetic status is not FDA drug approval. The safety of a complete eye-area product depends on more than the peptide name, and tolerability of one formulation cannot establish safety on damaged skin or by injection. Appearance claims should remain distinct from treatment claims for an underlying eye or systemic condition.
Supporting sources [4]
Reading this profile
Jurisdiction: United States; status and indications may differ elsewhere. Molecular class: Acetylated cosmetic tetrapeptide.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- Infraorbital tissue changes after a multi-component hyaluronic-acid/amino-acid intervention: single-arm study ↗Clinical trial source · Checked 2026-10-27
- Lubrizol: original Eyeseryl peptide solution G identity ↗Manufacturer / sponsor · Checked 2026-10-27
- Cayman Chemical: acetyl tetrapeptide-5 material identity and safety sheet ↗Manufacturer / sponsor · Checked 2026-10-27
- FDA: authority over cosmetics and the distinction from drug approval ↗Regulatory source · Checked 2026-10-27